The inhibitory effects of the 9-(2-phosphonylmethoxyethyl)adenine-related compounds (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)-adenine, (S)-9-(3-fluoro-2-phosphonylmethoxypropyl)adenine, (R)-9-(2-phosphonylmethoxypropyl)adenine, (R)-9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine, and (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine on human hepatitis B virus replication in the human hepatoma cell line HepG2 2.2.15 and duck hepatitis B virus infection in primary duck hepatocytes were investigated. (R)-9-(2-phosphonylmethoxypropyl-2,6-diaminopurine had the lowest 50%o inhibitory concentrations against hepatitis B virus and duck hepatitis B virus, 0.22 and 0.06 ,iM, respectively, i.e., two-to fivefold lower concentrations than required for (R)-9-(2-phosphonylmethoxypropyl)adenine and 9-(2-phosphonylmethoxyethyl)adenine. All compounds were not toxic in vitro at a concentration of 100 ,uM.
HepG2 2.2.15 and duck hepatitis B virus infection in primary duck hepatocytes were investigated. (R)-9-(2-phosphonylmethoxypropyl-2,6-diaminopurine had the lowest 50%o inhibitory concentrations against hepatitis B virus and duck hepatitis B virus, 0.22 and 0.06 ,iM, respectively, i.e., two-to fivefold lower concentrations than required for (R)-9-(2-phosphonylmethoxypropyl)adenine and 9-(2-phosphonylmethoxyethyl)adenine. All compounds were not toxic in vitro at a concentration of 100 ,uM.
In chronic hepatitis B virus (HBV) infection the basic therapy is the administration of interferon, although complete disappearance of virus markers is seldom observed. Hepatitis B e antigen seroconversion, reflecting a drastic decline of viral replication, is seen in only 20 to 40% of patients with HBV infections.
More potent antiviral drugs are eagerly awaited, and in light of this, the acyclic nucleoside phosphonates described earlier (3, 4) were considered adequate candidates to be further pursued for the treatment of HBV infections.
In an earlier study (6) we investigated the acyclic nucleoside phosphonate 9-(2-phosphonylmethoxyethyl)adenine (PMEA) in two hepatoma cell lines and primary duck hepatocytes. The 50% inhibitory concentrations (IC50) for human HBV and duck HBV (DHBV) were found to be 1.2 and 0.2 ,uM as measured in HepG2 2.2.15 cells and primary duck hepatocytes, respectively.
Among the acyclic nucleoside phosphonates several other derivatives were found to have high anti-DNA virus activity (herpes group) or antiretrovirus (human immunodeficiency virus [HIV] and Moloney murine sarcoma virus) activity (1) . The most effective HIV inhibitors among the acyclic nucleoside phosphonates were evaluated for their anti-HBV activities in the human hepatoma cell line HepG2 2.2.15. Two of the compounds, candidates for application with humans, were also assayed in primary duck hepatocytes infected with DHBV, in anticipation of studies with chronically DHBV-infected ducklings and chronic hepatitis B patients.
PMEA (5). The DHBV strain was kindly supplied by K. N. Tsiquaye (London, United Kingdom). Experimental conditions of cell culture for the human hepatoma cell line and the primary duck hepatocytes were as described before (6) . The culture medium of HepG2 2.2.15 cells was changed at day 3 after seeding and was supplemented with various concentrations of the drug. The culture medium, including the drug, was changed subsequently every third day. For DHBV-infected duck hepatocytes, the medium was changed at day 1 grams from dot spot hybridization, an LKB 222-020 Ultra Scan XL laser densitometer was used. The 50% cytotoxic concentration of (R)-PMPDAP and (R)-PMPA was >100 ,uM for both HepG2 2.2.15 cells and DHBV-infected duck hepatocytes (data not shown).
In summary, the high inhibitory effect of (R)-PMPDAP on hepadnavirus infections in both HepG2 2.2.15 cells and DHBV-infected duck hepatocytes is encouraging for further studies with ducks and humans.
